Daniel Rosebrock
Overview
Explore the profile of Daniel Rosebrock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
3657
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao Y, Kohl C, Rosebrock D, Hu Q, Hu Y, Vingron M
Nucleic Acids Res
. 2024 Jun;
52(13):e57.
PMID: 38850160
A fundamental analysis task for single-cell transcriptomics data is clustering with subsequent visualization of cell clusters. The genes responsible for the clustering are only inferred in a subsequent step. Clustering...
2.
Rosebrock D, Vingron M, Arndt P
iScience
. 2024 Mar;
27(4):109386.
PMID: 38500834
During cellular processes such as differentiation or response to external stimuli, cells exhibit dynamic changes in their gene expression profiles. Single-cell RNA sequencing (scRNA-seq) can be used to investigate these...
3.
Lareau C, Ludwig L, Muus C, Gohil S, Zhao T, Chiang Z, et al.
Nat Biotechnol
. 2023 Aug;
41(9):1345.
PMID: 37653227
No abstract available.
4.
Leshchiner I, Mroz E, Cha J, Rosebrock D, Spiro O, Bonilla-Velez J, et al.
Nat Cancer
. 2023 Apr;
4(4):550-563.
PMID: 37081260
Analysis of premalignant tissue has identified the typical order of somatic events leading to invasive tumors in several cancer types. For other cancers, premalignant tissue is unobtainable, leaving genetic progression...
5.
Gerstung M, Jolly C, Leshchiner I, Dentro S, Gonzalez S, Rosebrock D, et al.
Nature
. 2023 Jan;
614(7948):E42.
PMID: 36697833
No abstract available.
6.
Parry E, Leshchiner I, Guieze R, Johnson C, Tausch E, Parikh S, et al.
Nat Med
. 2023 Jan;
29(1):158-169.
PMID: 36624313
Richter syndrome (RS) arising from chronic lymphocytic leukemia (CLL) exemplifies an aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics underlying this transformation, we computationally deconvoluted admixtures...
7.
Rosebrock D, Arora S, Mutukula N, Volkman R, Gralinska E, Balaskas A, et al.
Nat Cell Biol
. 2022 Jun;
24(6):981-995.
PMID: 35697781
Cerebral organoids exhibit broad regional heterogeneity accompanied by limited cortical cellular diversity despite the tremendous upsurge in derivation methods, suggesting inadequate patterning of early neural stem cells (NSCs). Here we...
8.
Sun C, Chen Y, Zurita A, Baptista M, Pittaluga S, Liu D, et al.
Blood Adv
. 2022 Mar;
7(1):145-158.
PMID: 35358998
In chronic lymphocytic leukemia (CLL), B-cell receptor signaling, tumor-microenvironment interactions, and somatic mutations drive disease progression. To better understand the intersection between the microenvironment and molecular events in CLL pathogenesis,...
9.
Freeman S, Sade-Feldman M, Kim J, Stewart C, Gonye A, Ravi A, et al.
Cell Rep Med
. 2022 Mar;
3(2):100500.
PMID: 35243413
Immune checkpoint blockade (CPB) improves melanoma outcomes, but many patients still do not respond. Tumor mutational burden (TMB) and tumor-infiltrating T cells are associated with response, and integrative models improve...
10.
Dentro S, Leshchiner I, Haase K, Tarabichi M, Wintersinger J, Deshwar A, et al.
Cell
. 2021 Apr;
184(8):2239-2254.e39.
PMID: 33831375
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin, and drivers of ITH across cancer types are poorly understood. To...